{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T19:46:31Z","timestamp":1793303191164,"version":"4.5.0"},"reference-count":37,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2025,7,1]]},"abstract":"Importance<\/jats:title>Patients with advanced RET<\/jats:italic> fusion\u2013positive (RET<\/jats:italic>+<\/jats:sup>) non\u2013small cell lung cancer (NSCLC) who experience disease progression following treatment with RET<\/jats:italic> inhibitors (RETis) have limited treatment options. Identifying membrane protein targets may support the assessment of novel therapies, such as antibody-drug conjugates and bispecific antibodies.<\/jats:p><\/jats:sec>Objective<\/jats:title>To evaluate membrane target expression in RET<\/jats:italic>+<\/jats:sup> NSCLC.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This multicenter cohort study used centralized immunohistochemistry (IHC) on archival tissue samples and whole transcriptome sequencing (WTS) in an independent cohort. Tissue samples were collected from 12 European centers, and WTS was performed on globally sourced patient samples submitted for molecular profiling. This study included samples from patients with RET<\/jats:italic>+<\/jats:sup> NSCLC and RET<\/jats:italic>\u2013wild-type (RET<\/jats:italic>-wt) adenocarcinoma controls that were analyzed by IHC and 203 RET<\/jats:italic>+<\/jats:sup> and 19\u202f579 RET<\/jats:italic>-wt samples analyzed by WTS.<\/jats:p><\/jats:sec>Exposures<\/jats:title>Membrane protein expression of MET, ERBB2 (formerly HER2), epidermal growth factor receptor (EGFR), human epidermal growth factor 3 (HER3), and trophoblastic cell surface antigen 2 (TROP2) was evaluated using IHC, with samples scored on a scale of 0 to 3. Scores of 2 or greater were considered positive. Target expression as analyzed by WTS was expressed as median transcript per million scores.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Biomarker positivity, coexpression of biomarkers, dynamic changes in paired biopsies, and clinical correlates with survival outcomes.<\/jats:p><\/jats:sec>Results<\/jats:title>A total of 189 patients were included in the study (among 81 patients with RET<\/jats:italic>+<\/jats:sup> NSCLC, the median [IQR] age was 62 [55-70] years, and there were 49 female individuals [60%]). In 93 samples from 81 patients with RET<\/jats:italic>+<\/jats:sup> NSCLC, positive IHC scores were observed for MET in 51 of 86 (59%), ERBB2 in 3 of 84 (3.6%), EGFR in 24 of 84 (29%), HER3 in 31 of 82 (38%), and TROP2 in 59 of 65 (91%). Compared with RET<\/jats:italic>-wt adenocarcinoma (n\u2009=\u2009112), RET<\/jats:italic>+<\/jats:sup> tumors showed higher MET (59% vs 43%; P<\/jats:italic>\u2009=\u2009.03) and lower ERBB2 expression (3.6% vs 15%; P<\/jats:italic>\u2009=\u2009.01). The WTS analysis from the independent cohort confirmed these results. Of 61 evaluable samples, 59 of 61 (97%) had at least 1 positive biomarker, 60 of 77 (78%) when excluding TROP2<\/jats:italic>. MET<\/jats:italic>\/EGFR coexpression occurred in 17 of 79 evaluable samples (21.5%). Dynamic change in biomarker expression was observed in paired biopsy specimens. No significant survival differences based on target expression emerged in patients treated with RETi in the IHC and the WTS cohorts.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>The results of this cohort study suggest that RET<\/jats:italic>+<\/jats:sup> NSCLC tumors frequently express MET and TROP2, with MET positivity enriched vs RET<\/jats:italic>-wt controls. Coexpression and biomarker dynamics highlight the need for membrane target screening and novel therapeutic strategies for this population.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamaoncol.2025.1293","type":"journal-article","created":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T11:30:59Z","timestamp":1748518259000},"page":"762","source":"Crossref","is-referenced-by-count":3,"title":["Expression of Membrane Targets for Therapeutics in RET<\/i>-Positive Non\u2013Small Cell Lung Cancer"],"prefix":"10.1001","volume":"11","author":[{"given":"Arianna","family":"Marinello","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Gustave Roussy, International Center for Thoracic Cancers, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Rosa","family":"Ghigna","sequence":"additional","affiliation":[{"name":"Pathology and Molecular Biology Department, Gustave Roussy, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia K.","family":"Rotow","sequence":"additional","affiliation":[{"name":"Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tolulope","family":"Adeyelu","sequence":"additional","affiliation":[{"name":"Caris Life Sciences, Phoenix, Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulio","family":"Metro","sequence":"additional","affiliation":[{"name":"Medical Oncology, Ospedale Santa Maria della Misericordia, Perugia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Brand\u00e3o","sequence":"additional","affiliation":[{"name":"Clinic of Thoracic Oncology & Phase 1 Clinical Trials Unit, Institut Jules Bordet\u2013H\u00f4pital Universitaire de Bruxelles, Universit\u00e9 Libre de Bruxelles, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Guisier","sequence":"additional","affiliation":[{"name":"Department of Pneumology, Rouen University Hospital, Rouen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Monnet","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology, Intercommunal Hospital of Cr\u00e9teil, Cr\u00e9teil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hortense","family":"Gaultier de Saint Basile","sequence":"additional","affiliation":[{"name":"Pulmonary Medicine, H\u00f4pital Europ\u00e9en Georges Pompidou, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Genova","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Medical Specialties, University of Genoa, Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Raimbourg","sequence":"additional","affiliation":[{"name":"Institut de Canc\u00e9rologie de l\u2019Ouest, Saint-Herblain, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Safae","family":"Terrisse","sequence":"additional","affiliation":[{"name":"Medical Oncology, St Louis Hospital APHP, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Godefroy","sequence":"additional","affiliation":[{"name":"Plateforme de Pathologie Exp\u00e9rimentale et Translationnelle, UMS AMMICA, Gustave Roussy, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Toschi","sequence":"additional","affiliation":[{"name":"Medical Oncology, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Rozzano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Mandarano","sequence":"additional","affiliation":[{"name":"Section of Anatomic Pathology and Histology, Department of Medicine and Surgery, University of Perugia, Perugia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Doubre","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine, H\u00f4pital Foch, Suresnes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Russo","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Humanitas Istituto Clinico Catanese, Misterbianco, Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Valent","sequence":"additional","affiliation":[{"name":"Pathology and Molecular Biology Department, Gustave Roussy, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul Rafeh","family":"Naqash","sequence":"additional","affiliation":[{"name":"Stephenson Cancer Center, University of Oklahoma Health Sciences, Oklahoma City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayesha","family":"Aijaz","sequence":"additional","affiliation":[{"name":"Stephenson Cancer Center, University of Oklahoma Health Sciences, Oklahoma City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anas","family":"Gazzah","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Gustave Roussy, International Center for Thoracic Cancers, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Remon","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Gustave Roussy, International Center for Thoracic Cancers, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ari","family":"Vanderwalde","sequence":"additional","affiliation":[{"name":"Caris Life Sciences, Phoenix, Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Elliott","sequence":"additional","affiliation":[{"name":"Caris Life Sciences, Phoenix, Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balazs","family":"Halmos","sequence":"additional","affiliation":[{"name":"Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Barlesi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Gustave Roussy, International Center for Thoracic Cancers, Villejuif, France"},{"name":"Faculty of Medicine, Paris Saclay University, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Planchard","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Gustave Roussy, International Center for Thoracic Cancers, Villejuif, France"},{"name":"Faculty of Medicine, Paris Saclay University, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasi A.","family":"J\u00e4nne","sequence":"additional","affiliation":[{"name":"Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Besse","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Gustave Roussy, International Center for Thoracic Cancers, Villejuif, France"},{"name":"Faculty of Medicine, Paris Saclay University, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihaela","family":"Aldea","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Gustave Roussy, International Center for Thoracic Cancers, Villejuif, France"},{"name":"Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"},{"name":"Faculty of Medicine, Paris Saclay University, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"6","key":"coi250021r1","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1038\/bjc.2014.36","article-title":"RET-rearranged non-small-cell lung carcinoma: a clinicopathological and molecular analysis.","volume":"110","author":"Tsuta","year":"2014","journal-title":"Br J Cancer"},{"issue":"1","key":"coi250021r2","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.jtho.2015.09.016","article-title":"Clinicopathological characteristics of RET rearranged lung cancer in European patients.","volume":"11","author":"Michels","year":"2016","journal-title":"J Thorac Oncol"},{"issue":"7","key":"coi250021r3","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1080\/15384047.2015.1046649","article-title":"The RET fusion gene and its correlation with demographic and clinicopathological features of non-small cell lung cancer: a meta-analysis.","volume":"16","author":"Lin","year":"2015","journal-title":"Cancer Biol Ther"},{"issue":"5","key":"coi250021r4","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.jtho.2022.12.018","article-title":"RET-MAP: an international multicenter study on clinicobiologic features and treatment response in patients with lung cancer harboring a RET fusion.","volume":"18","author":"Aldea","year":"2023","journal-title":"J Thorac Oncol"},{"issue":"20","key":"coi250021r5","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1056\/NEJMoa2309457","article-title":"First-line selpercatinib or chemotherapy and pembrolizumab in RET fusion-positive NSCLC.","volume":"389","author":"Zhou","year":"2023","journal-title":"N Engl J Med"},{"issue":"7","key":"coi250021r6","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/S1470-2045(21)00247-3","article-title":"Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1\/2 study.","volume":"22","author":"Gainor","year":"2021","journal-title":"Lancet Oncol"},{"issue":"2","key":"coi250021r7","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1200\/JCO.22.00393","article-title":"Selpercatinib in patients with RET fusion\u2013positive non\u2013small-cell lung cancer: updated safety and efficacy from the registrational LIBRETTO-001 phase I\/II trial.","volume":"41","author":"Drilon","year":"2023","journal-title":"J Clin Oncol"},{"key":"coi250021r8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-02076","article-title":"Selpercatinib in RET fusion\u2013positive non\u2013small cell lung cancer: final safety and efficacy, including overall survival, from the LIBRETTO-001 phase I\/II trial.","author":"Gautschi","year":"2025","journal-title":"J Clin Oncol"},{"issue":"16","key":"coi250021r9","doi-asserted-by":"publisher","first-page":"9065","DOI":"10.1200\/JCO.2023.41.16_suppl.9065","article-title":"First results from the RETgistry: a global consortium for the study of resistance to RET inhibition in RET-altered solid tumors.","volume":"41","author":"Cooper","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"coi250021r10","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41698-022-00338-9","article-title":"Antibody-drug conjugates in lung cancer: dawn of a new era?","volume":"7","author":"Coleman","year":"2023","journal-title":"NPJ Precis Oncol"},{"key":"coi250021r11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2025.102902","article-title":"Antibody-drug conjugates in NSCLC with actionable genomic alterations: Optimizing smart delivery of chemotherapy to the target.","volume":"134","author":"Mountzios","year":"2025","journal-title":"Cancer Treat Rev"},{"issue":"3","key":"coi250021r12","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1056\/NEJMoa2112431","article-title":"Trastuzumab deruxtecan in HER2-mutant non\u2013small-cell lung cancer.","volume":"386","author":"Li","year":"2022","journal-title":"N Engl J Med"},{"issue":"31","key":"coi250021r13","doi-asserted-by":"publisher","first-page":"4852","DOI":"10.1200\/JCO.23.01361","article-title":"Trastuzumab deruxtecan in patients with HER2-mutant metastatic non\u2013small-cell lung cancer: primary results from the randomized, phase II DESTINY-Lung02 trial.","volume":"41","author":"Goto","year":"2023","journal-title":"J Clin Oncol"},{"issue":"4","key":"coi250021r14","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/S1470-2045(24)00064-0","article-title":"Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial.","volume":"25","author":"Smit","year":"2024","journal-title":"Lancet Oncol"},{"issue":"10","key":"coi250021r15","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.1038\/s41591-023-02554-7","article-title":"Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial.","volume":"29","author":"Cho","year":"2023","journal-title":"Nat Med"},{"issue":"16","key":"coi250021r16","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1056\/NEJMoa2403614","article-title":"Amivantamab plus lazertinib in previously untreated EGFR-mutated advanced NSCLC.","volume":"391","author":"Cho","year":"2024","journal-title":"N Engl J Med"},{"issue":"1","key":"coi250021r17","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.annonc.2023.10.117","article-title":"Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study.","volume":"35","author":"Passaro","year":"2024","journal-title":"Ann Oncol"},{"issue":"22","key":"coi250021r18","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1056\/NEJMoa2306441","article-title":"Amivantamab plus chemotherapy in NSCLC with EGFR exon 20 insertions.","volume":"389","author":"Zhou","year":"2023","journal-title":"N Engl J Med"},{"issue":"35","key":"coi250021r19","doi-asserted-by":"publisher","first-page":"5363","DOI":"10.1200\/JCO.23.01476","article-title":"HERTHENA-Lung01, a phase II trial of patritumab deruxtecan (HER3-DXd) in epidermal growth factor receptor\u2013mutated non\u2013small-cell lung cancer after epidermal growth factor receptor tyrosine kinase inhibitor therapy and platinum-based chemotherapy.","volume":"41","author":"Yu","year":"2023","journal-title":"J Clin Oncol"},{"issue":"5","key":"coi250021r20","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1200\/JCO.22.00739","article-title":"Phase Ib study of telisotuzumab vedotin in combination with erlotinib in patients with c-Met protein\u2013expressing non\u2013small-cell lung cancer.","volume":"41","author":"Camidge","year":"2023","journal-title":"J Clin Oncol"},{"key":"coi250021r21","doi-asserted-by":"publisher","first-page":"S805","DOI":"10.1016\/j.annonc.2024.08.1314","article-title":"1257MO ABBV-400, a c-Met protein-targeting antibody-drug conjugate (ADC), in patients (Pts) with advanced EGFR wildtype (WT) non-squamous (NSQ) non-small cell lung cancer (NSCLC): results from a phase I study.","volume":"35","author":"De Miguel","year":"2024","journal-title":"Ann Oncol"},{"key":"coi250021r22","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.01.001","article-title":"Results from a phase Ib study of telisotuzumab vedotin in combination with osimertinib in patients with c-Met protein-overexpressing, EGFR-mutated locally advanced\/metastatic non-small-cell lung cancer (NSCLC) after progression on prior osimertinib.","author":"Horinouchi","year":"2025","journal-title":"Ann Oncol"},{"issue":"10","key":"coi250021r23","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1200\/JCO-24-01349","article-title":"Datopotamab deruxtecan in advanced or metastatic non\u2013small cell lung cancer with actionable genomic alterations: results from the phase II TROPION-Lung05 study.","volume":"43","author":"Sands","year":"2025","journal-title":"J Clin Oncol"},{"issue":"32","key":"coi250021r24","doi-asserted-by":"publisher","first-page":"4105","DOI":"10.1200\/JCO.2012.47.4189","article-title":"Randomized phase II trial of onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer.","volume":"31","author":"Spigel","year":"2013","journal-title":"J Clin Oncol"},{"issue":"4","key":"coi250021r25","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1136\/jcp-2022-208632","article-title":"UK recommendations for HER2 assessment in breast cancer: an update.","volume":"76","author":"Rakha","year":"2023","journal-title":"J Clin Pathol"},{"key":"coi250021r26","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2023.101744","article-title":"Pan-tumor survey of RET fusions as detected by next-generation RNA sequencing identified RET fusion positive colorectal carcinoma as a unique molecular subset.","volume":"36","author":"Nagasaka","year":"2023","journal-title":"Transl Oncol"},{"issue":"4","key":"coi250021r27","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nmeth.4197","article-title":"Salmon provides fast and bias-aware quantification of transcript expression.","volume":"14","author":"Patro","year":"2017","journal-title":"Nat Methods"},{"issue":"17","key":"coi250021r28","doi-asserted-by":"publisher","first-page":"28725","DOI":"10.18632\/oncotarget.15647","article-title":"Association of tumor TROP2 expression with prognosis varies among lung cancer subtypes.","volume":"8","author":"Inamura","year":"2017","journal-title":"Oncotarget"},{"issue":"4","key":"coi250021r29","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1158\/1078-0432.CCR-23-2566","article-title":"TROP2 is associated with primary resistance to immune checkpoint inhibition in patients with advanced non\u2013small cell lung cancer.","volume":"30","author":"Bessede","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"2","key":"coi250021r30","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.ab.2004.12.026","article-title":"Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay.","volume":"338","author":"Parker","year":"2005","journal-title":"Anal Biochem"},{"issue":"13","key":"coi250021r31","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1200\/JCO.22.01900","article-title":"Efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression: results from the SORAYA study.","volume":"41","author":"Matulonis","year":"2023","journal-title":"J Clin Oncol"},{"issue":"10","key":"coi250021r32","doi-asserted-by":"publisher","first-page":"S25","DOI":"10.1016\/j.jtho.2024.09.050","article-title":"OA08.05 tusamitamab ravtansine vs docetaxel in previously treated advanced nonsquamous NSCLC: results from phase 3 CARMEN-LC03 trial.","volume":"19","author":"Besse","year":"2024","journal-title":"J Thorac Oncol"},{"issue":"16","key":"coi250021r33","doi-asserted-by":"publisher","first-page":"3023","DOI":"10.1200\/JCO.2024.42.16_suppl.3023","article-title":"A phase 1a\/b, multi-regional, first-in-human study of CS5001, a novel anti-ROR1 ADC, in patients with advanced solid tumors and lymphomas.","volume":"42","author":"Lemech","year":"2024","journal-title":"J Clin Oncol"},{"issue":"6","key":"coi250021r34","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1158\/1538-7445.AM2024-1885","article-title":"Abstract 1885: developing a biparatopic anti-ROR1 antibody drug conjugate BR111 for hematological and solid tumor treatment.","volume":"84","author":"Zhao","year":"2024","journal-title":"Cancer Res"},{"issue":"16","key":"coi250021r35","doi-asserted-by":"publisher","first-page":"8647","DOI":"10.1200\/JCO.2024.42.16_suppl.8647","article-title":"Bevacizumab in combination with chemotherapy for treating patients with advanced RET+ non\u2013small cell lung cancer.","volume":"42","author":"Aldea","year":"2024","journal-title":"J Clin Oncol"},{"issue":"7","key":"coi250021r36","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1001\/jama.2024.10613","article-title":"Ivonescimab plus chemotherapy in non\u2013small cell lung cancer with EGFR variant: a randomized clinical trial.","volume":"332","author":"Fang","year":"2024","journal-title":"JAMA"},{"issue":"10","key":"coi250021r37","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1016\/j.jtho.2024.09.015","article-title":"PL02.11 normalized membrane ratio of TROP2 by quantitative continuous scoring is predictive of clinical outcomes in TROPION-Lung 01.","volume":"19","author":"Garassino","year":"2024","journal-title":"J Thorac Oncol"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2834637\/jamaoncology_marinello_2025_oi_250021_1752269253.5132.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T15:00:56Z","timestamp":1752764456000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2834637"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":37,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2025.1293","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7,1]]}}}